Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tempest Therapeutics Inc.

6.90
-0.1900-2.68%
Post-market: 6.950.0493+0.71%19:54 EDT
Volume:79.87K
Turnover:562.22K
Market Cap:28.20M
PE:-0.35
High:7.18
Open:7.05
Low:6.90
Close:7.09
Loading ...

Tempest Therapeutics Inc. Files Prospectus for $6.25 Million Direct Offering to Fund Strategic Initiatives and Operations

Reuters
·
13 Jun

Tempest Therapeutics Announces $4.6 Million Registered Direct Offering of Common Stock to Institutional Investor

Reuters
·
11 Jun

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

THOMSON REUTERS
·
11 Jun

Tempest Therapeutics Inc - Announces Direct Offering of 739,000 Shares at $6.25 Each

THOMSON REUTERS
·
11 Jun

BRIEF-Tempest Therapeutics Terminates ATM Prospectus Supplement Dated February 6, 2025 - SEC Filing

Reuters
·
11 Jun

Tempest Therapeutics Inc - Terminates Atm Prospectus Supplement Dated February 6, 2025 - SEC Filing

THOMSON REUTERS
·
11 Jun

Tempest Therapeutics Suspends Prospectus Supplement, Halts Securities Sales Under Jefferies Agreement

Reuters
·
11 Jun

Top Premarket Gainers

MT Newswires Live
·
09 Jun

24H|Chinese ADRs Gain Ahead of US-China Trade Talks; AppLovin, Robinhood Dip Missing S&P 500 Inclusion

Tiger Newspress
·
09 Jun

Stocks to Watch: Children's Place, Tempest Therapeutics

Dow Jones
·
07 Jun

Tempest Therapeutics Inc. Announces Management Transition to Consulting Roles for CEO, CFO, and CMO

Reuters
·
07 Jun

Tempest Therapeutics Secures Orphan Drug Designation from European Medicines Agency for Amezalpat in Hepatocellular Carcinoma Treatment

Reuters
·
05 Jun

Tempest Receives Orphan Drug Designation From the European Medicines Agency for Amezalpat for the Treatment of Patients With Hcc

THOMSON REUTERS
·
05 Jun

Tempest Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
16 May

Tempest Therapeutics Inc expected to post a loss of $3.51 a share - Earnings Preview

Reuters
·
14 May

Tempest Therapeutics Reports Q1 2025 Results: Net Loss Widens to $10.9M, EPS at $3.16

Reuters
·
14 May

Tempest Therapeutics Inc expected to post a loss of $3.29 a share - Earnings Preview

Reuters
·
05 May

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

GlobeNewswire
·
29 Apr

Tempest Receives Orphan Drug Designation From the FDA for Tpst-1495 to Treat Patients With Fap

THOMSON REUTERS
·
21 Apr

Tempest Therapeutics Inc - Phase 2 Study of Tpst-1495 in Fap Patients to Begin This Year

THOMSON REUTERS
·
21 Apr